ClinicalTrials.gg
TerminatedNCT05014139Updated Sep 14, 2026

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

A Phase 1 interventional study of Enfortumab vedotin in Urinary Bladder Neoplasms, Carcinoma in Situ and Carcinoma Transitional Cell, sponsored by Astellas Pharma Global Development, Inc.. Terminated at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Primary conditionNon-Muscle Invasive Bladder NeoplasmsRegistry: Urinary Bladder NeoplasmsReclassifiedWhy we changed it
Registry
Urinary Bladder Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Muscle Invasive Bladder Neoplasms
Why
  1. The study's listed conditions name Non-Muscle Invasive Bladder Neoplasms, a narrower term within Urinary Bladder Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

Why this study was terminated
Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility, or request from regulatory authority, ethics committee, or institutional review board or EC/IRB.

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Enrollment
57th of 93
37 · median 55
Started
2021
with 7 others
Phase 1
20 of 114
5 open now
Registered
53rd of 114
by date

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 57th largest by enrollment of the 93 interventional ones that give a count, is one of 8 that started in 2021, is one of 20 in phase 1, and was the 53rd registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC).

This study will also evaluate what the side effects are and if the drug works to treat NMIBC. A side effect is anything a drug does to your body besides treating your disease.

In this study enfortumab vedotin will be put into the bladder using a catheter. A catheter is a thin tube that can be put into your bladder.

Read the detailed description

The study will be comprised of 2 parts. The first part (dose escalation) will find the highest dose of enfortumab vedotin that does not cause unacceptable side effects in participants. The second part (dose expansion) will use the dose found in the first part to test how well the drug works.

All participants will receive enfortumab vedotin. Treatment on the study will occur during the induction and maintenance phases, and participants will enter a follow-up period after completion of the maintenance phase.

03

Conditions studied

  • Urinary Bladder Neoplasms
  • Carcinoma in Situ
  • Carcinoma Transitional Cell
  • Non-muscle Invasive Bladder Cancer
  • NMIBC

Keywords

  • Bladder Cancer
  • Urothelial Cancer
  • Enfortumab vedotin
  • PADCEV
  • Pharmacokinetics
04

In context

Non-Muscle Invasive Bladder Neoplasms Reclassified

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

This study's enrollment of 37 is below the median of 62 across 231 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Bladder Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, non-muscle invasive urothelial carcinoma with carcinoma in situ (CIS) (with or without papillary disease)
  • Predominant histologic component (>50 percent) must be urothelial (transitional cell) carcinoma
  • Participants must have high-risk Bacillus Calmette-Guerin (BCG) - unresponsive disease, defined as (where adequate BCG therapy is defined as one of the following: 5 of 6 doses of an initial induction course + at least 2 of 3 doses maintenance therapy or 5 of 6 doses of an initial induction course + at least 2 of 6 doses of a second induction course):

    • Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy.
    • Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy, or
    • T1 high-grade disease at the first evaluation following an induction BCG course (at least 5 or 6 doses)
  • Participant must be ineligible for or refusing a radical cystectomy
  • All visible papillary Ta/T1 tumors must be completely resected within 60 days prior to enrollment.
  • Performance Status score of 0, 1, or 2.

Exclusion criteria

Exclusion Criteria:

  • Current or prior history of muscle-invasive urothelial carcinoma or disease.
  • Nodal or metastatic disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) within 3 months prior to study treatment
  • Concomitant upper tract urothelial carcinoma as noted on CT or MRI urogram performed within 3 months prior to study treatment
  • Prior or concomitant urothelial carcinoma of the prostatic urethra within 6 months prior to study treatment
  • Participants with tumor-related hydronephrosis
  • Participant has received other systemic anticancer therapy including chemotherapy, biologic therapy, immunotherapy, targeted therapy, endocrine therapy, and/or agent within 4 weeks or intravesical therapy within 6 weeks of first dose of study treatment
  • Participant has had any prior radiation to the bladder for urothelial cancer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Enfortumab vedotin: Dose escalation cohort

    During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.

    Drug: Enfortumab vedotin

  • Experimental
    Enfortumab vedotin: Dose expansion cohort

    During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.

    Drug: Enfortumab vedotin

Interventions

  • Given into the bladder (intravesically)

    Also known as: PADCEV, ASG-22CE, ASG-22ME

07

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    An AE is any untoward medical occurrence in a subject or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Approximately 1 year

  2. Incidence of laboratory abnormalities

    To be summarized using descriptive statistics.

    Time frame: Approximately 1 year

  3. Incidence of dose limiting toxicities (DLTs)

    To be summarized using descriptive statistics.

    Time frame: Approximately 7 weeks

Secondary outcomes

  1. Pharmacokinetics (PK) of enfortumab vedotin: Area under the concentration-time curve (AUC)

    AUC will be recorded from the PK blood samples collected.

    Time frame: Approximately 1 year

  2. PK of enfortumab vedotin: Maximum concentration (Cmax)

    Cmax will be recorded from the PK blood samples collected.

    Time frame: Approximately 1 year

  3. PK of enfortumab vedotin: Time to maximum concentration concentration (tmax)

    Tmax will be recorded from the PK blood samples collected.

    Time frame: Approximately 1 year

  4. PK of enfortumab vedotin: Apparent terminal half-life (t1/2)

    T1/2 will be recorded from the PK blood samples collected.

    Time frame: Approximately 1 year

  5. PK of enfortumab vedotin: Trough concentration (Ctrough)

    Ctrough will be recorded from the PK blood samples collected.

    Time frame: Approximately 1 year

  6. Incidence of antitherapeutic antibodies (ATAs) to enfortumab vedotin

    Blood samples for ATA analysis will be collected.

    Time frame: Approximately 1 year

  7. Complete response (CR) rate

    CR rate is defined as the proportion of subjects achieving CR.

    Time frame: Up to 24 months

  8. Duration of CR

    The time from first documented CR to the first evidence of recurrence, progression, or death due to any cause.

    Time frame: Up to 3.5 years

  9. Rate of cystectomy

    The proportion of subjects who subsequently undergo cystectomy.

    Time frame: Up to 3.5 years

  10. Progression-free survival

    The time from start of study treatment to the first evidence of progression or death due to any cause.

    Time frame: Up to 3.5 years

  11. Cystectomy-free survival

    The time from start of study treatment to cystectomy or death due to any cause.

    Time frame: Up to 3.5 years

08

Study locations

32 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • UCLA Department of Medicine - Hematology & Oncology
    Los Angeles, California 90095, United States
  • University of California, Irvine
    Orange, California 92868, United States
  • University of California at San Francisco
    San Francisco, California 94134, United States
  • Stanford Health Care
    Stanford, California 94305, United States
  • Northwestern University-Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Markey Cancer Center / University of Kentucky
    Lexington, Kentucky 40508, United States
  • Johns Hopkins Medical Center
    Baltimore, Maryland 21287, United States
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
    New York, New York 10016, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • James Cancer Hospital / Ohio State University
    Columbus, Ohio 43221, United States
  • Oregon Health and Science University
    Portland, Oregon 98682, United States
  • Sidney Kimmel Cancer Center
    Philadelphia, Pennsylvania 19107, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Erlanger Oncology and Hematology
    Chattanooga, Tennessee 37403, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • MD Anderson
    Houston, Texas 77030, United States
  • Urology San Antonio
    San Antonio, Texas 78229, United States
  • Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington
    Seattle, Washington 98195, United States
  • Site CA11001
    Toronto, Ontario M5G 2C1, Canada
  • Site FR33002
    Lyon, 69003, France
  • Site FR33001
    Paris, 75013, France
  • Site FR33003
    Rennes, 35000, France
  • Site DE49001
    Göttingen, 37075, Germany
  • Site DE49002
    Tübingen, 72076, Germany
  • Site ES34001
    Barcelona, 08025, Spain
  • Site ES34004
    Barcelona, 08035, Spain
  • Site ES34003
    Barcelona, 08036, Spain
  • Site ES34002
    Madrid, 28041, Spain
  • Site UK44002
    London, EC1A 7BE, United Kingdom
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Sep 2025, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2021
First posted
Aug 20, 2021
StartActual
Dec 7, 2021
Primary completionActual
Sep 22, 2025
CompletionActual
Sep 22, 2025
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05014139
Responsible party
Sponsor
First posted
Aug 20, 2021
Start date
Dec 7, 2021
Primary completion
Sep 22, 2025
Completion
Sep 22, 2025
Last update
Sep 14, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enfortumab vedotin

Start the discussion